title: Tenascin-cytotactin (TN-C) variants in pseudophakic/aphakic bullous keratopathy corneas.
abstract: OBJECTIVE
  To examine pseudophakic/aphakic bullous keratopathy (PBK/ABK) human corneas for patterns of expression of tenascincytotactin (TN-C) variants known to mediate specific cellular functions, viz. anti-adhesion (high molecular mass (M(r))) and adhesion (low/intermediate M(r)).
  
  
  METHODS
  PBK/ABK corneas were selected to encompass only those with bullae and without inflammation, scarring or neovascularisation. Serial sections from these and normal corneas were labelled with antibodies BC-4 (recognising all TN-C variants) and BC-2 (specific for the high M(r) TN-C variant). Bound antibody was revealed with an avidin-biotin peroxidase technique. In a given pair of corneal sections, positivity with BC-4 but not BC-2 indicates localisation of low/ intermediate M(r) TN-C variants and absence of the high M(r) TN-C variant. BC-2 identifies the high M(r) variant.
  
  
  RESULTS
  There was no immunostaining with either BC-2 or BC-4 in normal corneas except at the corneoscleral interface, where both BC-2 and BC-4 were immunolocalised. In PBK/ABK corneas, BC-2 staining was seen in 5 of 13 corneas and was restricted mainly to epithelial basement membrane (BM) overlying bullae. BC-2 did not label the stroma. BC-4 immunostaining was present in all PBK/ABK corneas and was localised in epithelial BM, both epithelial and stromal borders of bullae, pannus, endothelial BM and in oedematous stromal regions.
  
  
  CONCLUSIONS
  TN-C variants are differentially expressed in PBK/ABK corneas. The high M(r) variant is restricted mainly to epithelial BM overlying bullae, while low/intermediate M(r) variants occur in epithelial BM, both epithelial and stromal borders of bullae, and in pannus. Given the in vitro functions of TN-C, a role for promoting epithelial dehiscence and reattachment to the substratum in PBK/ABK corneas by high and low/intermediate M(r) variants respectively is likely.
authors.affiliation: Department of Ophthalmology, Royal Eye Hospital, Manchester, UK.
authors.forename: H
authors.initials: H
authors.lastname: Maseruka
authors.forename: S M
authors.initials: SM
authors.lastname: Ataullah
authors.forename: L
authors.initials: L
authors.lastname: Zardi
authors.forename: A B
authors.initials: AB
authors.lastname: Tullo
authors.forename: A E
authors.initials: AE
authors.lastname: Ridgway
authors.forename: R E
authors.initials: RE
authors.lastname: Bonshek
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001768:Blister / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D002387:Cataract Extraction / Q000009:adverse effects; D003316:Corneal Diseases / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D015715:Corneal Edema / Q000378:metabolism; D019573:Epithelium, Corneal / Q000378:metabolism; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D015948:Keratoplasty, Penetrating; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D019591:Pseudophakia / Q000378:metabolism*; D019063:Tenascin / Q000737:chemistry / Q000378:metabolism*
chemical_list: D019063:Tenascin